Healthcare Global Enterprises Ltd. (HCG), a leading cancer care provider operating 25 hospitals across India and Africa, is significantly increasing its investment in advanced oncology capabilities. The company announced plans to deploy Rs 425 crore, secured through a rights issue during FY26, into critical areas such as robotics, molecular diagnostics, genomics, and overall clinical infrastructure upgrades.
Advancing Precision Medicine and Early Diagnosis
The strategic investment reflects HCG's commitment to the evolving landscape of cancer care, which is shifting towards earlier diagnosis, targeted therapies, and integrated treatment pathways. Genomics and molecular diagnostics are expected to play an increasingly vital role in treatment planning and patient outcomes.
Dr. B. S. Ajaikumar, Founder and Non-Executive Chairman of HCG, emphasized this shift, stating, "Cancer care is no longer only about treatment. It is about early diagnosis, precision, continuity of care, and improving quality of life for patients and families." He added that the company's focus is on strengthening next-generation oncology capabilities, including data-driven clinical decision-making.
Capacity Expansion and Operational Strategy
The funds will also be utilized for capacity expansion and selective growth opportunities across HCG's extensive network. Demand for medical, radiation, and surgical oncology services remained steady throughout FY26, supported by improved patient throughput and better utilization rates across its centers.
HCG's integrated care model, which incorporates tumour-board-led clinical decision-making where specialists collaboratively review treatment options, remains central to its operational strategy. This approach ensures comprehensive and personalized care for patients.
"The successful completion of the rights issue has given the company flexibility to invest in long-term priorities," said Dr. Manish Mattoo, Chief Executive Officer, HCG. "This further strengthened our financial foundation and gives us greater flexibility to invest behind our long-term priorities, including capacity expansion, clinical infrastructure upgrades, technology investments and selective growth opportunities."
Dr. Mattoo further reiterated the company's commitment to improving utilization across its existing hospitals while selectively expanding its network to deliver high-quality, accessible cancer care.
Strong Financial Performance in FY26
For the fiscal year 2026, HCG reported robust financial results. Consolidated revenue from operations grew by 15% year-on-year to Rs 2,545 crore. Adjusted EBITDA saw a 19% increase, reaching Rs 471 crore, with the adjusted EBITDA margin improving to 18.5% from 17.8% in FY25, underscoring the company's strong operational efficiency.